|
270 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
39 Trials |
|
5519 News |
|
| «12...89101112131415161718...110111» |
- | Trial primary completion date: Effectiveness of Homeopathic Treatment in Female Infertility (clinicaltrials.gov) - Aug 8, 2017
P3, N=40, Recruiting, Sponsor: Fr Muller Homoeopathic Medical College
Trial primary completion date: Dec 2016 --> Dec 2017
- | Epogen (epoetin alfa) / Amgen
Trial completion: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Aug 8, 2017
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- | Trial completion, Trial initiation date, Trial primary completion date: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Aug 4, 2017
P3, N=623, Completed, Sponsor: Tulane University Health Sciences Center
Active, not recruiting --> Completed Recruiting --> Completed | Initiation date: Jun 2013 --> Oct 2014 | Trial primary completion date: Dec 2017 --> Jun 2017
- Vigil (gemogenovatucel-T) / Gradalis
Trial completion, Trial primary completion date, Tumor cell: Salvage Ovarian FANG (clinicaltrials.gov) - Aug 4, 2017
P2, N=1, Completed, Sponsor: Gradalis, Inc.
Recruiting --> Completed | Initiation date: Jun 2013 --> Oct 2014 | Trial primary completion date: Dec 2017 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
Trial primary completion date, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 3, 2017
P1, N=18, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016 Trial primary completion date: Oct 2014 --> Dec 2014
- | Trial completion, Trial primary completion date: ERROR: Endometrioma Related Reduced Ovarian Reserve (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=62, Completed, Sponsor: Uludag University
Trial primary completion date: Oct 2014 --> Dec 2014 Recruiting --> Completed | N=200 --> 62 | Trial primary completion date: May 2017 --> Aug 2017 | Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2017
- | Trial initiation date: Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=60, Completed, Sponsor: IVI Sevilla
Recruiting --> Completed | N=200 --> 62 | Trial primary completion date: May 2017 --> Aug 2017 | Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2017 Initiation date: May 2013 --> Oct 2013
- | Phase classification, PD(L)-1 Biomarker, IO biomarker, Gene therapy: T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers (clinicaltrials.gov) - Aug 2, 2017
P1/2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2013 --> Oct 2013 Phase classification: P2 --> P1/2
- | Trial completion: Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility (clinicaltrials.gov) - Aug 1, 2017
P=N/A, N=60, Completed, Sponsor: IVI Sevilla
Phase classification: P2 --> P1/2 Active, not recruiting --> Completed
- | paclitaxel / Generic mfg.
Trial completion: Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia (clinicaltrials.gov) - Aug 1, 2017
P2, N=32, Completed, Sponsor: Maimónides Biomedical Research Institute of Córdoba
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial completion: DESTINy: Diafert® for Embryo Selection and Fertility Improvement (clinicaltrials.gov) - Aug 1, 2017
P3, N=14, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Diafert for Embryo Selection and Fertility Improvement (DESTINy) (clinicaltrials.gov) - Aug 1, 2017
P3, N=108, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion, Trial primary completion date: DESTINy: Diafert for Embryo Selection and Fertility Improvement (clinicaltrials.gov) - Aug 1, 2017
P3, N=61, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Feb 2017
- || Talzenna (talazoparib) / Pfizer
Enrollment change, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 1, 2017
P1, N=113, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Feb 2017 N=74 --> 113
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma (clinicaltrials.gov) - Aug 1, 2017
P2, N=38, Completed, Sponsor: David O'Malley
N=74 --> 113 Active, not recruiting --> Completed
- | Enrollment change, Trial termination: To Evaluate if the Medication Gabapentin Lessens Vulvar Pain (clinicaltrials.gov) - Jul 31, 2017
P=N/A, N=9, Terminated, Sponsor: Colleen Stockdale
Active, not recruiting --> Completed N=40 --> 9 | Completed --> Terminated; poor recruitment
- ||| Trial completion: Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage (clinicaltrials.gov) - Jul 31, 2017
P=N/A, N=100, Completed, Sponsor: Forest Laboratories
N=40 --> 9 | Completed --> Terminated; poor recruitment Active, not recruiting --> Completed
- letrozole / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) - Jul 28, 2017
P2, N=9, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=80 --> 9 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Low accrual
- | Merional (menotropin) / IBSA Institute Biochemical SA, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
Trial primary completion date: AIPRICSI: Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (clinicaltrials.gov) - Jul 28, 2017
P4, N=20, Recruiting, Sponsor: Minia University
N=80 --> 9 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Low accrual Trial primary completion date: Apr 2017 --> Aug 2017
- ||| Qinprezo (vosaroxin) / Denovo
Enrollment change, Trial primary completion date: Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Jul 27, 2017
P2, N=183, Completed, Sponsor: Sunesis Pharmaceuticals
Trial primary completion date: Apr 2017 --> Aug 2017 N=143 --> 183 | Trial primary completion date: Oct 2010 --> Jun 2010
- | Biomarker, Trial completion, Enrollment change: TNF? and MFG-E8: Novel Biomarkers to Predict Implantation Failure (clinicaltrials.gov) - Jul 27, 2017
P=N/A, N=15, Completed, Sponsor: Eastern Virginia Medical School
N=143 --> 183 | Trial primary completion date: Oct 2010 --> Jun 2010 Enrolling by invitation --> Completed | N=30 --> 15
- Enrollment change, Trial termination, Trial primary completion date: Combining LHu With Ultrasound Monitoring in IUI (clinicaltrials.gov) - Jul 26, 2017
P=N/A, N=367, Terminated, Sponsor: OVO R & D
Enrolling by invitation --> Completed | N=30 --> 15 N=500 --> 367 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Aug 2016; sufficient participants for analysis
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Jul 25, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
N=500 --> 367 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Aug 2016; sufficient participants for analysis Trial primary completion date: Mar 2017 --> Sep 2017
- | metformin / Generic mfg.
Enrollment change: The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS (clinicaltrials.gov) - Jul 25, 2017
P4, N=101, Active, not recruiting, Sponsor: S.C.B. Medical College and Hospital
Trial primary completion date: Mar 2017 --> Sep 2017 N=152 --> 101
- | Trial completion, Enrollment change, HEOR: Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy (clinicaltrials.gov) - Jul 25, 2017
P=N/A, N=40, Completed, Sponsor: Brazilian National Cancer Institute
N=152 --> 101 Recruiting --> Completed | N=60 --> 40
- | TOL-463 / Toltec Pharma
Trial completion: TOL-463 Phase 2 Study for Vaginitis (clinicaltrials.gov) - Jul 24, 2017
P2, N=106, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=60 --> 40 Active, not recruiting --> Completed
- | dexamethasone / Generic mfg.
Trial primary completion date: dexFEM: Dexamethasone for Excessive Menstruation (clinicaltrials.gov) - Jul 23, 2017
P2, N=128, Recruiting, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Apr 2018
- | Trial completion: Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy (clinicaltrials.gov) - Jul 23, 2017
P=N/A, N=39, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Sep 2017 --> Apr 2018 Active, not recruiting --> Completed
- | Enrollment change, Trial termination: TOMOGYN: Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer (clinicaltrials.gov) - Jul 21, 2017
P3, N=26, Terminated, Sponsor: Centre Oscar Lambret
Active, not recruiting --> Completed N=60 --> 26 | Active, not recruiting --> Terminated; Recruitment difficulties
- | triptorelin / Generic mfg.
Trial completion: GTMLPSGI: GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT (clinicaltrials.gov) - Jul 21, 2017
P3, N=328, Completed, Sponsor: Centre Hospitalier Universitaire Ibn Rochd
N=60 --> 26 | Active, not recruiting --> Terminated; Recruitment difficulties Recruiting --> Completed
- | Trial completion, Trial primary completion date: Screening for Endometrial Abnormalities in Overweight and Obese Women (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=303, Completed, Sponsor: St. Luke's-Roosevelt Hospital Center
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Mar 2016
- | Phase classification, Trial primary completion date: ROBO-GYN: Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=386, Active, not recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Mar 2016 Phase classification: P3 --> P=N/A | Trial primary completion date: Jun 2017 --> May 2016
- | Phase classification: ANOXICOL: Study of a Predictor for Cervix Cancer (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=9, Terminated, Sponsor: Centre Oscar Lambret
Phase classification: P3 --> P=N/A | Trial primary completion date: Jun 2017 --> May 2016 Phase classification: P2 --> P=N/A
- ||| veliparib (ABT-888) / AbbVie
Trial completion, BRCA Biomarker: A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors (clinicaltrials.gov) - Jul 21, 2017
P1, N=71, Completed, Sponsor: AbbVie
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed
- Trial suspension: PISH-2: A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (clinicaltrials.gov) - Jul 21, 2017
P1, N=20, Suspended, Sponsor: ThermalCore Inc
Active, not recruiting --> Completed Recruiting --> Suspended
- | progesterone / Generic mfg.
Trial initiation date: Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF (clinicaltrials.gov) - Jul 19, 2017
P=N/A, N=12, Not yet recruiting, Sponsor: IVI Middle East Fertility Clinic
Recruiting --> Suspended Initiation date: Apr 2017 --> Jul 2017
- | Trial initiation date, Trial primary completion date: Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia (clinicaltrials.gov) - Jul 19, 2017
P1, N=40, Not yet recruiting, Sponsor: Washington University School of Medicine
Initiation date: Apr 2017 --> Jul 2017 Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jun 2018 --> Sep 2018
- ||| Talzenna (talazoparib) / Pfizer
Trial completion, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Jul 18, 2017
P1, N=74, Completed, Sponsor: Medivation, Inc.
Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study (clinicaltrials.gov) - Jul 18, 2017
P=N/A, N=70, Completed, Sponsor: Ain Shams University
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2017
- || zabedosertib (BAY1834845) / Bayer
Trial primary completion date: First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845 (clinicaltrials.gov) - Jul 18, 2017
P1, N=80, Recruiting, Sponsor: Bayer
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Sep 2017 --> Feb 2018
- || progesterone / Generic mfg.
Enrollment closed: The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=900, Active, not recruiting, Sponsor: Regionshospitalet Viborg, Skive
Trial primary completion date: Sep 2017 --> Feb 2018 Enrolling by invitation --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date: Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer (clinicaltrials.gov) - Jul 17, 2017
P1/2, N=15, Terminated, Sponsor: Dana-Farber Cancer Institute
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jan 2013
- | Trial completion, Enrollment change, Trial primary completion date, Metastases: FIRES: Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=490, Completed, Sponsor: Indiana University
Trial primary completion date: Dec 2014 --> Jan 2013 N=640 --> 490 | Trial primary completion date: May 2017 --> Jan 2017 | Recruiting --> Completed
- | cisplatin / Generic mfg.
Enrollment open: A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer (clinicaltrials.gov) - Jul 14, 2017
P3, N=540, Recruiting, Sponsor: Sun Yat-sen University
N=640 --> 490 | Trial primary completion date: May 2017 --> Jan 2017 | Recruiting --> Completed Not yet recruiting --> Recruiting
- | Karenitecin (cositecan) / BioNumerik
Trial primary completion date: Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 13, 2017
P2, N=27, Completed, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2008 --> Sep 2005
- | Trial primary completion date: CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 13, 2017
P2, N=78, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jul 2008 --> Sep 2005 Trial primary completion date: Jan 2008 --> Jul 2006
- |||| Papitrol (tirvalimogene teraplasmid) / Genexine, National OncoVenture
Trial completion, Trial primary completion date: Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - Jul 12, 2017
P2, N=72, Completed, Sponsor: Genexine, Inc.
Trial primary completion date: Jan 2008 --> Jul 2006 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Mar 2016
- | Karenitecin (cositecan) / BioNumerik
Trial completion: Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 12, 2017
P2, N=27, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Mar 2016 Active, not recruiting --> Completed
- | Trial completion: CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 12, 2017
P2, N=78, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Phase classification, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Jul 12, 2017
P, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Phase classification: P=N/A --> P | Phase classification: PN/A --> P1